BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 8306107)

  • 1. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P; White BP; Humphrey PP
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM; Jones RL; Wilson NH; Marr CG
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
    Ackerley N; Brewster AG; Brown GR; Clarke DS; Foubister AJ; Griffin SJ; Hudson JA; Smithers MJ; Whittamore PR
    J Med Chem; 1995 May; 38(10):1608-28. PubMed ID: 7752186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
    Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
    Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological actions of ICI 180080, a novel thromboxane receptor antagonist.
    Jessup CL; Jessup R; Wayne M
    J Pharm Pharmacol; 1986 Oct; 38(10):754-7. PubMed ID: 2878996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
    De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
    Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.
    McAuliffe SJ; Moors JA; Snow HM; Wayne M; Jessup R
    Br J Pharmacol; 1993 Apr; 108(4):901-6. PubMed ID: 8485629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
    J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.